Roche will acquire GeneWEAVE BioSciences, a US diagnostics company whose lead investor is China's Decheng Capital, for $425 million; WuXi PharmaTech, China's largest CRO/CMO, formally accepted the $3.3 billion merger offer that will take the company private; Ascentage Pharma of Shanghai closed a $15.5 million Round A financing to develop its oncology portfolio; FortuneRock (China), a Beijing clinical-stage biotech, has been approved to IPO and list its shares on China's Third Board; Hua Medicine of Shanghai reported that its GKA treatment for Type 2 diabetes was very effective in a Phase Ic trial; Singapore's ASLAN Pharma received US Orphan Drug Designation for a bile duct cancer treatment; and WuXi PharmaTech and TruTag Technologies of Hawaii completed a test of TruTag's nanotechnology security technology in solid dose drugs.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
